CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials

被引：124
|
作者：
Maisey, NR [1 ]
Norman, AR [1 ]
Hill, A [1 ]
Massey, A [1 ]
Oates, J [1 ]
Cunningham, D [1 ]
机构：
[1] Royal Marsden Hosp, Dept Med, Sutton SM2 5PT, Surrey, England
来源：
BRITISH JOURNAL OF CANCER | 2005年 / 93卷 / 07期
关键词：
pancreatic cancer; CA19-9; prognosis; chemotherapy;
D O I：
10.1038/sj.bjc.6602760
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In a multivariate analysis of 154 patients receiving chemotherapy, baseline CA19-9 was an independent prognostic factor for overall survival (OS) (HR 1.8; 95% CI: 1.3 - 2.5, P = 0.0004). The 1-year OS was 19 and 46%, respectively, for patients with a baseline CA19-9 above or below the median value. A fall of 20% in CA19-9 level from baseline was an independent prognostic factor for OS ( HR 1.9; 95% CI: 1.1 - 3.4, P = 0.019).
引用
收藏
页码：740 / 743
页数：4
相关论文
共 50 条
  • [1] CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials
    N R Maisey
    A R Norman
    A Hill
    A Massey
    J Oates
    D Cunningham
    British Journal of Cancer, 2005, 93 : 740 - 743
  • [2] Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer
    Asaoka, Tadafumi
    Miyamoto, Atsushi
    Maeda, Sakae
    Tsujie, Masanori
    Hama, Naoki
    Yamamoto, Kazuyoshi
    Miyake, Masakazu
    Haraguchi, Naotsugu
    Nishikawa, Kazuhiro
    Hirao, Motohiro
    Ikeda, Masataka
    Sekimoto, Mitsugu
    Nakamori, Shoji
    PANCREATOLOGY, 2016, 16 (03) : 434 - 440
  • [3] CA19-9 as a Prognostic Biomarker in Pancreatic Neuroendocrine Tumors
    Luo, G.
    Guo, M.
    Liu, Z.
    Liu, C.
    Cheng, H.
    Lu, Y.
    Jin, K.
    Zhang, B.
    Liu, L.
    Long, J.
    Xu, J.
    Ni, Q.
    Chen, J.
    Yu, X.
    NEUROENDOCRINOLOGY, 2016, 103 : 49 - 49
  • [4] Prognostic impact of the ratio of preoperative CA19-9 to liver enzyme levels in pancreatic cancer patients with jaundice (predictability of combined CA19-9/AST and CA19-9/γ-GGT for jaundiced PDAC patients)
    Huang, Xumin
    Lu, Zipeng
    Zhang, Kai
    Wang, Guangfu
    Cai, Baobao
    Wu, Pengfei
    Yin, Jie
    Miao, Yi
    Jiang, Kuirong
    PANCREATOLOGY, 2021, 21 (06) : 1092 - 1101
  • [5] Serum CA19-9 determination in the management of pancreatic cancer
    vandenBosch, RP
    vanEijck, CHJ
    Mulder, PGH
    Jeekel, J
    HEPATO-GASTROENTEROLOGY, 1996, 43 (09) : 710 - 713
  • [6] CA19-9 decrease and survival according to platelet level in patients with advanced pancreatic cancer
    Chen, Y.
    Wang, Y. R.
    Deng, G. C.
    Dai, G. H.
    BMC CANCER, 2019, 19 (01)
  • [7] Duration of Reduced CA19-9 Levels Is a Better Prognostic Factor Than Its Rate of Reduction for Unresectable Locally Advanced Pancreatic Cancer
    Tomishima, Ko
    Ishii, Shigeto
    Fujisawa, Toshio
    Ikemura, Muneo
    Ota, Hiroto
    Kabemura, Daishi
    Ushio, Mako
    Fukuma, Taito
    Takahashi, Sho
    Yamagata, Wataru
    Takasaki, Yusuke
    Suzuki, Akinori
    Ito, Koichi
    Saito, Hiroaki
    Nagahara, Akihito
    Isayama, Hiroyuki
    CANCERS, 2021, 13 (16)
  • [8] CA19-9 Reduction After 4 Months of Treatment Is a Prognostic Factor for Locally Advanced Pancreatic Cancer
    Mie, Takafumi
    Ozaka, Masato
    Okamoto, Takeshi
    Takeda, Tsuyoshi
    Ushida, Yuta
    Mori, Chinatsu
    Furukawa, Takaaki
    Yamada, Yuto
    Kasuga, Akiyoshi
    Matsuyama, Masato
    Sasaki, Takashi
    Inoue, Yousuke
    Takahashi, Yu
    Sasahira, Naoki
    IN VIVO, 2022, 36 (06): : 2844 - 2851
  • [9] CA19-9 for detecting recurrence of pancreatic cancer
    Azizian, Azadeh
    Ruehlmann, Felix
    Krause, Tanja
    Bernhardt, Markus
    Jo, Peter
    Koenig, Alexander
    Kleiss, Mathias
    Leha, Andreas
    Ghadimi, Michael
    Gaedcke, Jochen
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [10] Diagnostic and Prognostic Value of CEA and CA19-9 in Colorectal Cancer
    Lakemeyer, Leilani
    Sander, Silvia
    Wittau, Mathias
    Henne-Bruns, Doris
    Kornmann, Marko
    Lemke, Johannes
    DISEASES, 2021, 9 (01)
12345